Delagil (Delagil)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceChlorokhinChlorokhin
Similar drugsTo uncover
  • Delagil
    pills inwards 
    Meda Pharma GmbH & Co. KG     Germany
    • Dosage form: & nbsppills
    Composition:

    1 the tablet contains:

    chloroquine phosphate 250.0 mg;

    Excipients: corn starch 55.0 mg; silicon colloidal hydrophobic (Aerosil R 972) 2.0 mg; polyacrylic acid (Carbomer 934 P) 5.0 mg; magnesium stearate 2.0 mg; talc 10.0 mg; polyvinyl butyral (Movital B 30 T) 26.0 mg.

    Description:

    Flat tablets with beveled edges, white or almost white, odorless.

    Pharmacotherapeutic group:Anti-malarial drug
    ATX: & nbsp

    P.01.B.A.01   Chlorokhin

    Pharmacodynamics:

    Anti-protozoal, it also has an immunosuppressive and anti-inflammatory effect. Causes the death of asexual erythrocytic forms of all species of plasmodia. Has a gametocidal effect, with the exception of Plasmodium falciparum (exhibits antihametocidal effect.

    Pharmacokinetics:After oral administration, it is quickly and almost completely absorbed from the gastrointestinal tract. The maximum concentration in the blood is reached after 2-6 hours. 55% is associated with albumin plasma. Rapidly spreads to the organs and tissues of the body (liver, kidneys, spleen, lungs). Easily penetrates the blood-brain barrier and the placenta. Metabolized in small amounts (25%). It is excreted by the kidneys (70% - unchanged) slowly.Half-life period 1-2 months. With renal dysfunction can cumulate.
    Indications:

    Malaria (prevention and treatment of all types), extraintestinal amebiasis, amoebic liver abscess, systemic lupus erythematosus (SLE) (chronic and subacute), rheumatoid arthritis, scleroderma, photodermatosis.

    Contraindications:

    Hypersensitivity, hepatic and / or renal failure, oppression of bone marrow hematopoiesis, severe rhythm disturbances, psoriatic arthritis, neutropenia, porphyrinuria, pregnancy, lactation.

    Carefully:Deficiency of glucose-6-phosphate dehydrogenase, retinopathy, epilepsy.
    Dosing and Administration:

    Inside, for the prevention of malaria - for 0.5 g in the first week 2 times, then 1 time always on the same day of the week. Treatment of malaria is carried out according to the following scheme: 1 day once 1 g, after 6-8 h - 0.5 g, on the 2nd and 3rd day of treatment - 0.75 g daily in one session. With amebiasis, 0.5 g 3 times a day for 7 days, then 0.25 g 3 times a day for a further 7 days, then 0.75 g 2 times a week for 2-6 months. With rheumatoid arthritis - 0.25 g 2 times a day for 7 days, then 0.25 g daily for 12 months.

    With SLE - every day, at 0.25-0.5 g.

    With photodermatosis, 0.25 g daily for a week, then 0.5-0.75 g weekly.

    Side effects:

    From the digestive system: nausea, vomiting, gastralgia.

    From the nervous system: dizziness, headache, sleep disturbances, psychoses, epileptic seizures.

    From the cardiovascular system: myocardial damage with changes on the electrocardiogram (ECG), lowering of blood pressure.

    From the senses: with prolonged use - corneal opacity, retinal damage, visual impairment, ringing in the ears.

    Allergic reactions: dermatitis, photosensitivity.

    Other: myalgia, leukopenia, discoloration of the skin and hair.

    Overdose:

    Symptoms: vomiting, impaired consciousness, visual disturbances, convulsions, collapse, oppression of the respiratory center, until the fatal outcome (within 2 hours of respiratory depression). Treatment: invocation of vomiting, gastric lavage, intake of activated charcoal in a dose 5 times higher than the estimated dose of chloroquine; peritoneal dialysis, plasmapheresis.

    Interaction:

    Co-administration with phenylbutazone, gold preparations, penicillamine, cytostatics, levamisole increases the probability of bone marrow aplasia and skin lesions.

    Antacids interfere with absorption, cimetidine increases the concentration of the drug in the blood.The combination with other antimalarial drugs may be accompanied by an antagonistic effect.
    When combined with glucocorticosteroids, the risk of myopathy and cardiomyopathy increases, with monoamine oxidase (MAO) inhibitors, the risk of developing neurotoxicity increases, with ethanol - hepatotoxicity, with cardiac glycosides - glycoside intoxication
    Special instructions:

    During the period of treatment, systematic examinations of the ophthalmologist and general blood tests are necessary.

    Form release / dosage:

    Tablets of 250 mg.

    Packaging:

    10 tablets per blister.

    3 blisters along with the instruction are placed in a cardboard box.

    Storage conditions:

    List B.

    In a place inaccessible to children, at a temperature of no higher than 25 ° C.

    Shelf life:

    5 years. After expiration date the drug should not be used.

    Terms of leave from pharmacies:On prescription
    Registration number:П N016127 / 01
    Date of registration:02.12.2009 / 09.02.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:Meda Pharma GmbH & Co. KGMeda Pharma GmbH & Co. KG Germany
    Manufacturer: & nbsp
    Representation: & nbspMEDA PHARMA LLCMEDA PHARMA LLC
    Information update date: & nbsp23.03.2017
    Illustrated instructions
      Instructions
      Up